Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 ⁺ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

Mary A. Vogler, Hedy Teppler, Rebecca Gelman, Fred Valentine, Michael M. Lederman, Roger J. Pomerantz, Richard B. Pollard, Deborah Weng Cherng, Charles J. Gonzalez, Kathleen E. Squires, Ian Frank, Donna Mildvan, Laura F. Mahon, Barbara Schock

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 ⁺ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)'. Together they form a unique fingerprint.

Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 ⁺ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

Fingerprint

Keyphrases

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions

Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 + T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

Fingerprint

Keyphrases

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions

Daily Low-Dose Subcutaneous Interleukin-2 Added to Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4 ⁺ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)